Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California-San Francisco
San Francisco, California, United States
- Loyola University Medical Center
Maywood, Illinois, United States
- Indiana University
Indianapolis, Indiana, United States
- John Hopkins University
Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber at Faulkner Hospital
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Cape Cod Healthcare
Hyannis, Massachusetts, United States
- Lowell General Hospital
Lowell, Massachusetts, United States
- North Shore Medical Center
Peabody, Massachusetts, United States
- Washington University
St Louis, Missouri, United States
- North Shore Lij Health System Monter Cancer Center
Lake Success, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Weill Cornell Medical College
New York, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
- Case Western University
Cleveland, Ohio, United States
- Tennessee Oncology
Nashville, Tennessee, United States
- University of Vermont Cancer Center
Burlington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2007
- Primary completion
- 21 Apr 2014
- Completion
- 30 Aug 2022
- Last update posted
- 26 Jun 2024
- Registered enrollment
- 406
- Registry id
- NCT00542451
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.